





## Extending thrombolysis to 4.5-9 hours and wake-up stroke using perfusion imaging:

## A meta-analysis of individual patient data from EXTEND, ECASS4-EXTEND and EPITHET

Bruce Campbell<sup>\*</sup>, <u>Henry Ma</u><sup>\*</sup>, Peter Ringleb<sup>\*</sup>, Mark Parsons, Leonid Churilov, Werner Hacke<sup>#</sup>, Stephen Davis<sup>#</sup> and Geoffrey Donnan<sup>#</sup>

on Behalf of EXTEND, ECASS4-EXTEND and EPITHET Investigators

\* # Contributed Equally





















## **Background and Hypothesis**

- <u>Background</u>: Currently thrombolysis is recommended up to **4.5 hours** after ischemic stroke onset and wake up stroke patients are excluded
- **Perfusion mismatch** identifies patients who benefit from reperfusion therapy (thrombectomy) up to 24 hours after onset.
- <u>Hypothesis</u>: Intravenous alteplase improves functional outcome in ischemic stroke patients more than 4.5 hours (up to 9 hours) and wake up stroke who have perfusion mismatch (CT or MRI)
- We performed an individual patient data meta-analysis of **EXTEND**, **ECASS4-ExTEND** and **EPITHET** to test the hypothesis

## **Result and Conclusion**

- Alteplase improves excellent functional outcomes (mRS 0-1) at 3 months when administered 4.5-9h or after wake-up stroke <9h from midpoint of sleep in patients with perfusion mismatch (adjusted odd ratio 1.86 95% CI 1.15-2.99 p=0.011)
- Alteplase archived higher rate of good functional outcome, reperfusion, recanalization compared to placebo
- **Consistent** effect in age, time, Large vessel strata
- **sICH increased** but did not negate the net benefit in ordinal analysis
- Mortality not significantly different
- Both benefit and risk **similar** to 0-4.5h alteplase
- Benefit predominantly seen in the patients with automated perfusion mismatch
- Now it is time to extend the thrombolysis time window to 9 hours and for patients with wake up stroke